Hunt says the positive response rates reported at three months after treatment were sustained at 12 months after treatment, with seven people still showing a “clinically relevant improvement”.
ReNeuron's Michael Hunt discusses very encouraging long-term stroke data
Quick facts: ReNeuron Group PLC
Price: 92.551 GBX
Market Cap: £29.5 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of ReNeuron Group PLC named herein, including the promotion by the Company of ReNeuron Group PLC in any Content on the Site, the Company receives...FOR OUR FULL DISCLAIMER CLICK HERE